The FDA is encouraging drug developers to turn to new technology to help them monitor clinical trial work without resorting to frequent site visits, according to a report in Outsourcing-Pharma. In a new set of proposed guidelines, regulators specifically cited electronic data capture and statistical assessments to help them monitor the quality of the studies they sponsor. But no company, regulators add, should call a halt to their on-site visits. Story